These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15149145)

  • 1. Accomplishments and perspectives of immunological interventions in lymphoproliferative disorders.
    Milosević DB
    J Exp Clin Cancer Res; 2004 Mar; 23(1):9-13. PubMed ID: 15149145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine strategies to treat lymphoproliferative disorders.
    Radford KJ; Vari F; Hart DN
    Pathology; 2005 Dec; 37(6):534-50. PubMed ID: 16373232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of dendritic cell vaccines.
    Morse MA; Lyerly HK
    Curr Opin Mol Ther; 2000 Feb; 2(1):20-8. PubMed ID: 11249649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell vaccination for cancer therapy.
    Nestle FO
    Oncogene; 2000 Dec; 19(56):6673-9. PubMed ID: 11426654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiotypic vaccination in B-cell malignancies.
    Bianchi A; Massaia M
    Mol Med Today; 1997 Oct; 3(10):435-41. PubMed ID: 9358470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
    Leitch HA; Connors JM
    Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of idiotype vaccines in the treatment of human B-cell malignancies.
    Bendandi M
    Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DC-based immunotherapy of B-cell malignancies.
    Reichardt VL; Brossart P
    Cytotherapy; 2004; 6(1):62-7. PubMed ID: 14985168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
    J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines for lymphomas: idiotype vaccines and beyond.
    Houot R; Levy R
    Blood Rev; 2009 May; 23(3):137-42. PubMed ID: 18951668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
    Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
    Ackermann B; Tröger A; Glouchkova L; Körholz D; Göbel U; Dilloo D
    Klin Padiatr; 2004; 216(3):176-82. PubMed ID: 15175963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of hematological malignancies using dendritic cells.
    Van de Velde AL; Berneman ZN; Van Tendeloo VF
    Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell-based immunotherapy.
    Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
    Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The preparation of anticancer vaccine for patients with multiple myeloma on the base of monoclonal immunoglobulin loaded dendritic cells].
    Ocadlíková D; Zahradová L; Kovárová L; Smejkalová J; Pour L; Vidláková P; Kyjovská D; Moravcová J; Rycová M; Novotná H; Jelínková I; Penka M; Michálek J; Hájek R
    Klin Onkol; 2009; 22(2):67-72. PubMed ID: 19522376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
    Fredriksen AB; Sandlie I; Bogen B
    Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.